NEW YORK – Single-cell proteomics firm IsoPlexis said Tuesday that it has received a $2 million Small Business Innovation Research (SBIR) grant from the National Institute on Aging of the National Institutes of Health.
The Phase 2 grant is for work the company is doing to analyze the proteomic responses of trafficking leukocytes in patients with Alzheimer's disease and related neurodegenerative conditions.